Plain-English translation of NCT06663111 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether rituximab works as well as ocrelizumab in treating relapsing-remitting multiple sclerosis. You would receive one of these two medications and give blood samples at scheduled times so researchers can measure how much of the medication is in your system and see if drug levels relate to how well the treatment works.
Doctors want to know if rituximab could be an effective alternative to ocrelizumab for newly diagnosed patients. By measuring medication levels in the blood, researchers hope to learn whether personalized dosing based on blood tests could help tailor treatment to individual patients.
You likely qualify if…
You likely don't qualify if…
You will be part of a 30-month study where you take one of two medications for multiple sclerosis. At set points during your treatment, you'll visit a laboratory to have blood samples drawn so researchers can measure how much medication is in your blood and check other markers of how your body is responding. The study is double-blinded, meaning neither you nor your doctors will know which medication you're receiving.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Norway
Collaborators
University of Bergen
Enrollment target
~60 participants
Started
March 2021
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Trond T. Serkland, M.D.
Haukeland University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.